Back to results
US 2025/0082634 A1Published application
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
AssigneesSumitomo Pharma America, Inc., The Research Foundation for The State University of New York
InventorsJason Marc FOULKS, Steven L. WARNER, Golam MOHI
Life of this patent
Estimating the term…
Abstract
Methods for treatment of myeloproliferative neoplasms and/or fibrosis associated with cancer are provided. The disclosed methods comprise administering a PIM kinase inhibitor, and optionally a JAK kinase inhibitor or other therapeutic agent, to a mammal in need thereof.
Claims1
A method for treating a myeloproliferative neoplasm in a mammal in need thereof, the method comprising administering to the mammal:
- from about 250 mg to about 2.5 g per day of a compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof;
- and
- an effective amount of ruxolitinib, or a pharmaceutically acceptable salt thereof.
1 more element
Dependencies are inferred from the claim text.